Short Term Price Target on Pfizer (PFE)

Pfizer (NYSE:PFE) : The highest short term price target forecast on Pfizer (NYSE:PFE) is $54 and the lowest target price is $33. A total of 13 equity analysts are currently covering the company. The average price of all the analysts is $38.92 with a standard deviation of $5.56.

Shares of Pfizer Inc. rose by 1.79% in the last five trading days and 1.32% for the last 4 weeks. Pfizer Inc. is up 18.26% in the last 3-month period. Year-to-Date the stock performance stands at 11.16%. Also, Major Brokerage house, Jefferies maintains its ratings on Pfizer (NYSE:PFE). In the latest research report, Jefferies lowers the target price from $42 per share to $40 per share. According to the latest information available, the shares are now rated Buy by the analysts at the agency. The rating by the firm was issued on June 20, 2016.

Pfizer (NYSE:PFE) : Zacks Investment Research ranks Pfizer (NYSE:PFE) as 1, which is a Strong Buy recommendation. 9 research analysts consider that the stocks fundamentals point to a bright future, hence they rate the stock as a Strong Buy. A total of 6 analysts believe that the stock has a limited upside, hence they advise a Hold. The average broker rating of 15 research analysts is 1.8, which indicates as a Buy.

Pfizer (NYSE:PFE): During Thursdays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $35.14 and $34.94 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $35.27. The buying momentum continued till the end and the stock did not give up its gains. It closed at $35.21, notching a gain of 0.57% for the day. The total traded volume was 26,993,796 . The stock had closed at $35.01 on the previous day.

In an insider trading activity, The Securities and Exchange Commission has divulged that Damelio Frank A, officer (Executive Vice President) of Pfizer Inc, had unloaded 100,000 shares at an average price of $34.49 in a transaction dated on May 26, 2016. The total value of the transaction was worth $3,449,000.

Pfizer Inc. is a global biopharmaceutical company. The Company is engaged in discovering, developing and manufacturing of healthcare products. Its products include Lyrica, the Prevnar family of products, Enbrel, Celebrex, Lipitor, Viagra, Zyvox, Sutent, EpiPen, Toviaz, Tygacil, Rapamune, Xalkori, Inlyta, Norvasc, BeneFIX, Genotropin and Enbrel, among others. It operates in three segments: Global Innovative Pharmaceutical segment (GIP), Global Vaccines, Oncology and Consumer Healthcare segment (VOC) and Global Established Pharmaceutical segment (GEP). GIP is focused on developing, registering and commercializing medications in therapeutic areas, such as inflammation, cardiovascular/metabolic, neuroscience and pain, rare diseases and womens/mens health. VOC focuses on the development and commercialization of vaccines and products for oncology and consumer healthcare. GEP includes its sterile injectable products and bio similar development portfolio. Its subsidiary is Hospira, Inc.

Leave a Reply

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.